Definitive Contract 75N93020C00042
Award Date
9/1/20
Potential Completion Date
8/31/22
Potential Value
$600K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Antagen Biosciences Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Boston, MA 02118, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000 definitive contract to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, as part of the Small Business Innovation Research Program Phase I Action. The contract is a firm fixed price award with a period of performance from July 5, 2022 through November 30, 2023 to be performed in Canton, Massachusetts. The award is set aside for...
This federal contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID) to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals. The $599,997.00 contract is a Firm Fixed Price Definitive Contract under the SBIR Program Phase I Action for the Major Program Code DAIDS. The purpose of the contract is to evaluate and modulate the molecular pathways involved in regulating and...
This is a $599,914 firm-fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Antagen Biosciences Inc. (doing business as Antagen Pharmaceuticals), a small disadvantaged and minority-owned biotechnology company. The objective of this SBIR Phase I research contract is to develop a nanoparticle-based vaccine delivery platform to induce broadly neutralizing antibodies against HIV. The work will...
This $1,000,000 firm-fixed-price SBIR Phase II contract was awarded by the Centers for Disease Control and Prevention (CDC) to Antagen Biosciences Inc., a minority-owned, small disadvantaged business. The contract is for research and development of an engineered HIV envelope glycoprotein and novel vaccine adjuvants to enhance the efficacy of vaccines against infectious and immune-mediated diseases. This award is part of Antagen's broader portfolio of SBIR contracts, including prior awards from...
Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, has been awarded a $299,998 firm fixed price Small Business Innovation Research (SBIR) contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. Under this contract, Antagen will further develop its novel protein nanoparticle-based expression and delivery system using FcRider technology and antibody afucosylation technology to produce an engineered HIV envelope glycoprotein...
This $599,526 Firm Fixed Price contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Enepret Incorporated, a for-profit manufacturer located in Lexington, Kentucky. The contract is for "Adjuvant Discovery and Down-Selection for Vaccines against Infectious and Immune-Mediated Diseases" and supports NIAID's broader program goals related to "A More Durable and Universal Adjuvanted...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to the nonprofit research institute Access To Advanced Health Institute (AAHI), also known as Aahi, Idri, and Infectious Disease Research Institute. The contract is for the development of vaccine candidates for biodefense, antimicrobial resistant (AMR) infections, and emerging infectious...
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside for...
This is a $224,981.00 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to Epitogenesis Inc., a minority-owned, economically disadvantaged women-owned small business. The contract is for the development of "A NUTRITIVE VACCINE ADJUVANT AGAINST INFLUENZA" and has a period of performance ending on September 14, 2015. The contract was set aside for small businesses.
This $600,000 firm fixed price contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Adjuvax LLC of Birmingham, Alabama. The contract is being performed under SBIR Topic 106 to develop adjuvant mimics in support of the NIH and CDC's missions. The solicitation sought proposals for Small Business Innovation Research contracts across numerous technical topics aligned with improving public health. This award is set aside for total...